Sign in
4

Changes in Ownership

Vaxcyte, Inc. Filed Acc 0001649094-24-000082

PRESIDENT AND CFO sold 42,000 shares at an average $115.39 ($4,846,508)

  • PRESIDENT AND CFO acquired 42,000 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
GUGGENHIME ANDREW PRESIDENT AND CFO 2024-10-18 Option exercise 10b5-1 +8,000 $5.35 $42,800 98,383 D
GUGGENHIME ANDREW PRESIDENT AND CFO 2024-10-18 Option exercise 10b5-1 +8,000 $5.35 $42,800 106,383 D
GUGGENHIME ANDREW PRESIDENT AND CFO 2024-10-18 Option exercise 10b5-1 +12,000 $5.35 $64,200 118,383 D
GUGGENHIME ANDREW PRESIDENT AND CFO 2024-10-18 Option exercise 10b5-1 +14,000 $5.35 $74,900 132,383 D
GUGGENHIME ANDREW PRESIDENT AND CFO 2024-10-18 Sale 10b5-1 −36,114 $115.26 $4,162,608 96,269 D
GUGGENHIME ANDREW PRESIDENT AND CFO 2024-10-18 Sale 10b5-1 −5,886 $116.19 $683,900 90,383 D
Derivatives
GUGGENHIME ANDREW PRESIDENT AND CFO 2024-10-18 Option exercise · Stock Option (right to buy) 10b5-1 −8,000 312,827 D
GUGGENHIME ANDREW PRESIDENT AND CFO 2024-10-18 Option exercise · Stock Option (right to buy) 10b5-1 −8,000 304,827 D
GUGGENHIME ANDREW PRESIDENT AND CFO 2024-10-18 Option exercise · Stock Option (right to buy) 10b5-1 −12,000 292,827 D
GUGGENHIME ANDREW PRESIDENT AND CFO 2024-10-18 Option exercise · Stock Option (right to buy) 10b5-1 −14,000 278,827 D
Open-market sales · 42,000 sh · avg $115.39 · $4,846,508
Loading xslF345X05/wk-form4_1729627909.xml…